Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects.
Location: United Kingdom, England, London
Member count: 11-50
Total raised: $35.621265M
Founded date: 2012
Investors 2
| Date | Name | Website |
| - | Korea Inve... | partners.k... |
| - | Flerie Inv... | flerie.com |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 09.02.2023 | - | $30M | Flerie Inv... | forbes.com... |
| 08.10.2019 | - | $5.621265M | - | finsmes.co... |
Mentions in press and media 3
| Date | Title | Description | Category | Author | Source |
| 09.02.2023 | Microbial ... | Prokarium CEO Kristen Albright... | - | - | forbes.com... |
| 12.10.2021 | Wacker Che... | Go to selection pageBackForwar... | - | - | marketscre... |
| 08.10.2019 | Prokarium ... | Prokarium, a London, UK-based ... | UK | - | finsmes.co... |